Search Results

There are 5903 results for: content related to: The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-IgE in Persistent Severe Allergic Asthma

    Allergy and Allergic Diseases, Volume 1, Second Edition

    Marc Humbert, Stephen T. Holgate, Howard Fox, Jean Bousquet, Pages: 1661–1686, 2009

    Published Online : 10 FEB 2009, DOI: 10.1002/9781444300918.ch81

  3. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders


    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Version of Record online : 24 APR 2015, DOI: 10.1111/all.12616

  4. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Version of Record online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  5. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy


    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Version of Record online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  6. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma


    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Version of Record online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  7. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment

    British Journal of Dermatology

    Volume 173, Issue 2, August 2015, Pages: 404–415, M.C. Urgert, M.T. van den Elzen, A.C. Knulst, Z. Fedorowicz and E.J. van Zuuren

    Version of Record online : 22 JUL 2015, DOI: 10.1111/bjd.13845

  8. Omalizumab (Xolair): Anti-Immunoglobulin E Treatment in Allergic Diseases

    Handbook of Therapeutic Antibodies

    Claus Kroegel, Martin Foerster, Pages: 951–997, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch37

  9. Omalizumab may not inhibit mast cell and basophil activation in vitro

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 9, September 2015, Pages: 1832–1836, J. Gericke, T. Ohanyan, M.K. Church, M. Maurer and M. Metz

    Version of Record online : 26 SEP 2014, DOI: 10.1111/jdv.12693

  10. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Version of Record online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  11. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Data from 17 patients

    Arthritis & Rheumatology

    Accepted manuscript online: 4 MAR 2016, Marie Jachiet, Maxime Samson, Vincent Cottin, Jean-Emmanuel Kahn, Guillaume Le Guenno, Philippe Bonniaud, Hervé Devilliers, Laurence Bouillet, Anne Gondouin, Fatma Makhlouf, Nadine Meaux-Ruault, Helder Gil, Boris Bienvenu, André Coste, Matthieu Groh, Violaine Giraud, Stéphane Dominique, Bertrand Godeau, Xavier Puéchal, Chahera Khouatra, Marc Ruivard, Claire Le Jeunne, Luc Mouthon, Loïc Guillevin, Benjamin Terrier and for the French Vasculitis Study Group (FVSG)

    DOI: 10.1002/art.39663

  12. You have free access to this content
    Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

    Journal of the European Academy of Dermatology and Venereology

    Volume 30, Issue S5, July 2016, Pages: 25–32, A. M. Giménez-Arnau, E. Toubi, A. M. Marsland and M. Maurer

    Version of Record online : 10 JUN 2016, DOI: 10.1111/jdv.13697

  13. You have free access to this content
    Management and treatment of chronic urticaria (CU)

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue S3, June 2015, Pages: 16–32, M. Maurer, M.K. Church, M. Gonçalo, G. Sussman and M. Sánchez-Borges

    Version of Record online : 4 JUN 2015, DOI: 10.1111/jdv.13198

  14. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR


    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Version of Record online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  15. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Version of Record online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x

  16. You have full text access to this OnlineOpen article
    Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

    Clinical & Experimental Allergy

    Volume 44, Issue 11, November 2014, Pages: 1371–1385, J. P. Arm, I. Bottoli, A. Skerjanec, D. Floch, A. Groenewegen, S. Maahs, C. E. Owen, I. Jones and P. J. Lowe

    Version of Record online : 21 OCT 2014, DOI: 10.1111/cea.12400

  17. Immunoglobulin E Blockade in the Treatment of Asthma

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 10, October 2007, Pages: 1412–1424, Robert Kuhn

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.10.1412

  18. You have free access to this content
    Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma


    Volume 66, Issue 5, May 2011, Pages: 671–678, J. Bousquet, Z. Siergiejko, E. Świebocka, M. Humbert, K. F. Rabe, N. Smith, J. Leo, C. Peckitt, R. Maykut and G. Peachey

    Version of Record online : 21 JAN 2011, DOI: 10.1111/j.1398-9995.2010.02522.x

  19. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

    Internal Medicine Journal

    Accepted manuscript online: 28 JUN 2016, Peter G Gibson, Helen Reddel, Vanessa M McDonald, Guy Marks, Christine Jenkins, Andrew Gillman, John Upham, Michael Sutherland, Janet Rimmer, Frank Thien, Greg P Katsoulotos, Matthew Cook, Ian Yang, Connie Katelaris, Simon Bowler, David Langton, Paul Robinson, Craig Wright, Veronica Yozghatlian, Scott Burgess, Pathmanathan Sivakumaran, Adam Jaffe, Jeff Bowden, Peter AB Wark, Kwok Y Yan, Vicky Kritikos, Matthew Peters, Mark Hew, Ali Aminazad, Michael Bint and Michael Guo

    DOI: 10.1111/imj.13166

  20. Impact of omalizumab on medical cost of childhood asthma in Japan

    Pediatrics International

    Volume 58, Issue 5, May 2016, Pages: 425–428, Hideki Yoshikawa, Mihoko Iwata, Hiroshi Matsuzaki, Rintaro Ono, Yoko Murakami, Naohiko Taba, Satoshi Honjo, Chikako Motomura and Hiroshi Odajima

    Version of Record online : 13 MAY 2016, DOI: 10.1111/ped.12936